Hisse Senetlerindeki Sıralama
#16218
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on... Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Hisse Fiyatı
$3.70
Son senkronizasyon: 2026-07-31
Ticaret Opus Genetics, Inc. (IRD)
B piyasa değeri ile IRD fiyatı
Piyasa Değeri Opus Genetics, Inc.(IRD)
Piyasa Değeri: $305.87M
September 2026 itibarıyla Opus Genetics, Inc. şirketinin piyasa değeri $305.87M. Bu, verilerimize göre Opus Genetics, Inc. şirketini dünyanın en değerli 16218th. şirketi yapar. Piyasa değeri, halka açık bir şirketin tedavüldeki hisse senetlerinin toplam piyasa değeri olup, bir şirketin değerini ölçmek için yaygın olarak kullanılır.
Opus Genetics, Inc. piyasa değeri geçmişi (2024 - 2026)
En Popüler 5 stocks ile karşılaştırıldığında IRD
| IRD’in Fiyatı |
|
B Varlığı |
B’nin Piyasa Değeri |
Sonuçlar |
|
|
|
|
$5.260T
|
+1,719,438.14%
|
|
|
|
|
$4.779T
|
+1,562,157.96%
|
|
|
|
|
$4.017T
|
+1,313,103.81%
|
|
|
|
|
$3.719T
|
+1,215,863.74%
|
|
|
|
|
$2.734T
|
+893,812.25%
|
